INVEGA SUSTENNA® Common Dosing and Administration Topics

Maintenance Dosing

Management of Missed Maintenance Dose

Consistent with the INVEGA SUSTENNA® Prescribing Information:

  • In case of a missed maintenance dose follow the dosing instructions provided in the Table.

Table: Management of a Missed Maintenance Dose.

Timing of Missed Maintenance Dose Dosing
4 to 6 weeks since first injection Resume regular monthly dosing as soon as possible at the patient's previously stabilized dose, followed by injections at monthly intervals.
More than 6 weeks to 6 months since last injection Resume the same dose the patient was previously stabilized on (unless the patient was stabilized on a dose of 234 mg, then the first 2 injections should each be 156 mg) in the following manner:
  1. Administer a deltoid injection as soon as possible.
  2. Administer a second deltoid injection 1 week later at the same dose.
  3. Thereafter, resume administering the previously stabilized dose in the deltoid or gluteal muscle 1 month after the second injection.
More than 6 months since last injection Restart dosing with recommended initiation:
  1. Administer a 234 mg deltoid injection on Day 1.
  2. Administer a 156 mg deltoid injection 1 week later.
  3. Thereafter, resume administering the previously stabilized dose in the deltoid or gluteal muscle 1 month after the second injection.

For illustrative displays of this dosing scenario, please click the link(s) below.

Missed Maintenance Dose: 4 to 6 Weeks Since Last Injection for Schizoaffective Disorder

Missed Maintenance Dose: >6 Weeks to 6 Months Since Last Injection for Schizoaffective Disorder

Missed Maintenance Dose: >6 Months Since Last Injection for Schizoaffective Disorder

Educational Dose Illustrator for:
INVEGA SUSTENNA® (paliperidone palmitate)
INVEGA TRINZA® (paliperidone palmitate)

The Educational Dose Illustrator can be used to visualize how dosing affects paliperidone plasma concentrations following administration of:

INVEGA SUSTENNA® for:

  • the treatment of schizophrenia in adults
  • the treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants

INVEGA TRINZA® for:

  • the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA® for at least four months.

This resource simulates the paliperidone plasma concentrations over time resulting from different dosing scenarios that are set forth in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. The Educational Dose Illustrator is intended to be used as a resource to foster a better understanding of, and educate healthcare professionals about, the dosing recommendations provided in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. It is intended for educational purposes only.

Because the simulated patient paliperidone plasma levels shown in the dosing scenarios are based upon aggregated pharmacokinetic information from clinical studies, the simulations may not be representative of individual patient response.

Please Acknowledge

The information contained in this web site is intended for US healthcare professionals only. Privacy Policy.

© Janssen Scientific Affairs, LLC 2024. All rights reserved. cp-45525v5

This site is published by Janssen Scientific Affairs, LLC, which is solely responsible for its contents.

This information is intended for healthcare providers in the United States only.

Last updated 8/22/2023

Please Confirm

×

Thank you for visiting the Educational Dose Illustrator.

By clicking "Continue" below, you will be taken to a website where our Privacy Policy does not apply. You are solely responsible for your interactions with such websites.

We encourage you to read the Privacy Policy of every website you visit. Please view our Privacy Policy at your convenience.

Continue Cancel